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a summary of the presentations made at the Second
International Workshop of the OsteoArthritis Research
Society International (OARSI) held in Florence, Italy from
15–17 October, 1998. This Workshop was created in
order to review the most recent and challenging concepts
regarding the pathophysiology and treatment of osteo-
arthritis (OA). Recent discoveries on the role of nitric oxide
(NO) in the disease process and its role as a potential
treatment target were strong incentives in selecting this
topic as part of our program. Time justified our choice, as a
few days prior to the opening of our Workshop, the 1998
Nobel Prize for Medicine was awarded to three scientists
whose research significantly contributed to improving the
understanding of the role played by nitric oxide (NO) in
human physiology. Moreover, recent advances in the field
of prostaglandin research has stirred up excitement with
regard to the development of new and better drugs for the
treatment of OA symptoms. As a result, it was thought that
this topic, along with the former, would be the perfect
chemistry for a most interesting and exhilarating Workshop.
And thus, the workshop on NO and cyclooxygenase (COX)
was born.
Numerous informative presentations addressed the
issue concerning the role of NO in the pathophysiology of
OA. The potential cellular and tissular sources of NO in the
joint were also reviewed. Other interesting topics included
the progress made at identifying the cell signaling systems
and the identification of metabolic pathways involved in the
production of NO. Several observations clearly linked the
excess production of NO with several abnormal metabolic
functions of chondrocytes identified in OA tissue, such as
the decrease in the repair capacity of this tissue because of
the reduced capacity of those cells to synthesize new
matrix macromolecules. Also presented was the discovery
of NO’s ability to decrease the synthesis of the interleukin 1
receptor antagonist (IL-1Ra), enhance apoptosis and
inhibit B-1 integrin dependent adhesion to the extracellular
matrix. Experimental data strongly suggest that the
selective inhibition or deletion of iNOS may reduce the
progression of the structural changes of the disease.
Papers presented at the Florence Workshop also
demonstrated that prostaglandins are produced in sig-
nificant quantities by osteoarthritic cartilage. This is not
apparent if synovial tissue alone is examined where
cyclooxygenase 2 (COX-2) expression is minimal, particu-
larly when compared to rheumatoid arthritic (RA) synovial
tissue. However, COX-2 is upregulated in chondrocytes
present in both OA and RA cartilage specimens. At the
meeting, it was reported that OA cartilage specimens
spontaneously produce significant amounts of prostaglan-
din (PG) E2 at levels 50-fold times higher than normal
cartilage and 18-fold higher than those produced by nor-
mal cartilage stimulated with cytokines and endotoxin.359The importance of IL-1 produced by OA chondrocytes
was emphasized since the addition of IL-1 antagonists to
OA explant cultures inhibited the ‘spontaneous’ production
of PGE2.
Several presentations at the Workshop also addressed
the following important question: What are the effects of PG
overproduction in OA? Since cartilage is an avascular,
aneural tissue, PGs produced by chondrocytes do not
readily induce the classical signs of inflammation in
OA—namely, heat, redness, swelling and pain. Rather, it
was postulated by investigators in Florence that OA PGs
act locally in an autocrine/paracrine fashion to regulate
matrix homeostasis. In vitro, certain effects have been
described that suggest a possible reparative role for PGs.
For example, it was reported that PGE2 reverses proteo-
glycan degradation induced by IL-1 in bovine and human
cartilage explants, inhibits IL-1â-induced metalloprotease
(MMP; e.g., collagenase, stromelysin) expression in human
synovial fibroblasts and enhances collagen type II and
proteoglycan synthesis. It was also reported at the Work-
shop that PGs stimulate the expression of Type II collagen
gene expression in transfected human chondrocytes. Con-
versely, data were presented which indicate that PGs
promote cartilage matrix degradation. For example, PGE2
activates MMPs, as has been reported in epithelial cells
and human synoviocytes. Recently, it has been observed
that PGE2 increases stromelysin production by cartilage.
Thus, in vitro, COX products exert both anabolic and
catabolic effects on matrix metabolism, with the ‘net’ result
on cartilage integrity being uncertain at present. This is an
extremely critical area that will require further basic and
clinical investigation.
A satellite symposium addressed regulatory issues
related to the conduct of clinical trials for structure (disease)
modifying agents for OA. This program, organized by
Jean-Yves Reginster and Roy Altman created an open
discussion on the special issues related to this form of
clinical research. The application of OA disease specific
metrologies was discussed. Existing imaging method-
ologies and criteria for radiographic assessment were
discussed. Finally, guidelines were presented for the
evaluation of radiographic studies on OA of the hip and
knee.
We would like to thank the members of the Organizing
Committee: Professor Steffen S. Gay, Professor Stefan
Lohmander, Professor Wim van den Berg for their import-
ant contribution to the organization of this meeting, our
local organizer, Professor Umberto Semi for his work,
dedication and patience, and our organizing secretariat,
and in particular Ms Letizia Rossi and Mr Roberto
Bucciarelli for assisting the Society in organizing the
Workshop in such a wonderful city. A very special thank you
to two very special people who dedicated their time, efforts
and part of their personal lives in making this meeting a
360 Forewordsuccess. We would like at this time to acknowledge the
outstanding work performed by our Workshop Executive
Director, Ms Santa Fiori, Secretary to Professor Jean-
Pierre Pelletier and Ms Madeline Rios, Secretary to Profes-
sor Steven Abramson. This meeting would not have been
possible without their competence.
We would like to thank the organizations who supported
our Society in the past, and in the present, as well as our
corporate members who have very significantly contributed
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Osteoarthritis and Cartilage Journal for allowing us the
opportunity to publish this issue and Professor Roy Altman
for his exceptional work in the preparation of this special
issue. We would also like to acknowledge all those whom
we unfortunately neglected to mention. Thank you one and
all for making the OsteoArthritis Research Society Inter-
national and this Second International Workshop a reality
and a success.
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